title: Binding of high-density lipoproteins to luteal membranes: the role of prolactin, luteinizing hormone, and circulating lipoproteins.
abstract: Ovarian and adrenal membranes from immature gonadotropin-primed rats, treated with 4-amino-pyrazolopyrimidine (4APP) to reduce endogenous lipoprotein levels, displayed higher binding of porcine high-density lipoprotein (HDL) when compared to control rats. Immature, hypophysectomized (HYPOX) rats bearing corpora lutea (CL) on Day 5 after ovulation had lower levels of serum progesterone and reduced capacity for HDL and human chorionic gonadotropin (hCG) binding to ovarian membranes when compared with intact animals. Hypophysectomy also reduced the number of HDL binding sites in adrenal membranes. Treatment of HYPOX animals with luteinizing hormone (LH) and prolactin (Prl) alone or in combination increased the HDL binding sites in the ovary relative to HYPOX-untreated rats. Neither hormone affected binding to adrenals, where only adrenocorticotropic hormone (ACTH) enhanced HDL binding. LH treatment reduced the serum progesterone levels and hCG binding to the ovaries, whereas Prl administration increased progesterone levels with no effect on hCG binding. We conclude from this study that HDL binding in the luteinized ovary is regulated by Prl and LH and circulating lipoproteins, whereas in adrenals it is regulated by ACTH and circulating levels of lipoproteins.
authors.forename: K
authors.initials: K
authors.lastname: Rajkumar
authors.forename: R L
authors.initials: RL
authors.lastname: Couture
authors.forename: B D
authors.initials: BD
authors.lastname: Murphy
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000311:Adrenal Glands / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D006063:Chorionic Gonadotropin / Q000378:metabolism; D003338:Corpus Luteum / Q000166:cytology / Q000378:metabolism*; D004338:Drug Combinations; D005260:Female; D007016:Hypophysectomy; D007455:Iodine / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000494:pharmacology / Q000502:physiology*; D008566:Membranes / Q000378:metabolism; D010053:Ovary / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D013552:Swine; D013997:Time Factors
chemical_list: D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D008074:Lipoproteins; D008075:Lipoproteins, HDL; C004420:4-aminopyrazolo(3,4-d)pyrimidine; D011374:Progesterone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D007455:Iodine; D000225:Adenine